Colon Cancer Liquid Biopsy Investigation of Methylation-based Biomarkers Evaluation Using Delta-HLD (CLIMBED)
Recruiting · NCT07168876 · Observational (researchers observe without assigning treatment) · Lead sponsor: Epiliquid Holding, Inc
View the official record on ClinicalTrials.gov →What this trial is about
CLIMBED (Colon cancer Liquid biopsy Investigation of Methylation-based Biomarkers Evaluation using Delta-HLD) is a non-randomized, observational, cross-sectional clinical validation study designed to assess the performance of Delta-HLD, Epiliquid's proprietary liquid biopsy technology, for colorectal cancer (CRC) detection. The study will evaluate the test performance in an average-risk population for CRC undergoing screening colonoscopy, which will serve as the gold standard reference.
Who can take part
Age range
45 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Men and women aged 45-75 years
- Indication of colorectal cancer screening colonoscopy by treating physician
Exclusion criteria
- First-degree family history of CRC
- Inflammatory bowel disease (ulcerative colitis, Crohn's disease)
- Other malignancies within 5 years
- Known hereditary CRC syndromes (Lynch, FAP)
- Major trauma, surgery, transfusion in past 30 days
- Current participation in an interventional clinical trial
Where it is running
1 location listed.
- Epiliquid - Mendoza, Mendoza Province, Argentina